慧博雲通(301316.SZ):目前尚未進行ChatGPT相關的底層神經網絡算法的技術研發
格隆匯4月25日丨有投資者在投資者互動平台向慧博雲通(301316.SZ)提問,“貴公司目前有進行ChatGPT相關的底層神經網絡算法的技術研發嗎?”
慧博雲通回覆稱,公司目前尚未進行ChatGPT相關的底層神經網絡算法的技術研發。公司的業務模式為基於各大廠商的神經網絡算法技術,提供下游人工智能產品及解決方案的開發及實施,如招股書中披露,在自然語言處理領域,公司為客户提供人工智能應用集成服務產品包括在線智能機器客服、智能文字/語音問答系統、智能音箱等。同時人工智能業務在公司整體業務中佔比不大,請投資人注意投資風險。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.